HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...

Takeda is to acquire TiGenix, the stem cell specialist biotech with which it has developed a gastro stem cell therapy, in a deal worth 520 million euros ($626 million). The decision follows ...

The global enzyme replacement therapy market size was valued at USD 10.12 billion in 2024 and is projected to grow from USD 11.35 billion in 2025 to reach USD 21.29 billion by 2033, exhibiting a CAGR ...

In February 2024, the government slashed GST (Goods and Services Tax) from three major cancer drugs: Trastuzumab Deruxtecan, ...

The list of 36 drugs, which are exempt from basic customs duty, includes many expensive and imported medicines that can ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...

Takeda is promoting U.S. chief Julie Kim to be ... The first phase of expansion at the Danish plant just added six new mammalian cell bioreactors, and the next phase is being backed by $1.6 ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. The company called the ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...